CN102892409B - 用于保存铝盐佐剂和铝盐-佐剂化疫苗的方法 - Google Patents

用于保存铝盐佐剂和铝盐-佐剂化疫苗的方法 Download PDF

Info

Publication number
CN102892409B
CN102892409B CN201180014386.6A CN201180014386A CN102892409B CN 102892409 B CN102892409 B CN 102892409B CN 201180014386 A CN201180014386 A CN 201180014386A CN 102892409 B CN102892409 B CN 102892409B
Authority
CN
China
Prior art keywords
adjuvant
sucrose
concentration
drying
sugar
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201180014386.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN102892409A (zh
Inventor
杰弗里·德鲁
戴维·伍德华德
阿曼达·科尔泰恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Stabilitech Ltd
Original Assignee
Stabilitech Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1005518.4A external-priority patent/GB201005518D0/en
Priority claimed from GBGB1005522.6A external-priority patent/GB201005522D0/en
Application filed by Stabilitech Ltd filed Critical Stabilitech Ltd
Publication of CN102892409A publication Critical patent/CN102892409A/zh
Application granted granted Critical
Publication of CN102892409B publication Critical patent/CN102892409B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/131—Amines acyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CN201180014386.6A 2010-03-31 2011-03-31 用于保存铝盐佐剂和铝盐-佐剂化疫苗的方法 Expired - Fee Related CN102892409B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1005518.4A GB201005518D0 (en) 2010-03-31 2010-03-31 Preservation of alum-adjuvanted vaccines
GB1005522.6 2010-03-31
GBGB1005522.6A GB201005522D0 (en) 2010-03-31 2010-03-31 Method for preserving alum-adjuvanted vaccines
GB1005518.4 2010-03-31
PCT/GB2011/000497 WO2011121305A2 (en) 2010-03-31 2011-03-31 Method for preserving alum adjuvants and alum-adjuvanted vaccines

Publications (2)

Publication Number Publication Date
CN102892409A CN102892409A (zh) 2013-01-23
CN102892409B true CN102892409B (zh) 2015-12-09

Family

ID=43971221

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180014386.6A Expired - Fee Related CN102892409B (zh) 2010-03-31 2011-03-31 用于保存铝盐佐剂和铝盐-佐剂化疫苗的方法

Country Status (13)

Country Link
US (1) US9101607B2 (OSRAM)
EP (1) EP2552410B1 (OSRAM)
JP (1) JP6023696B2 (OSRAM)
KR (1) KR101819250B1 (OSRAM)
CN (1) CN102892409B (OSRAM)
AU (1) AU2011234268B2 (OSRAM)
BR (1) BR112012025044A2 (OSRAM)
CA (1) CA2795050C (OSRAM)
DK (1) DK2552410T3 (OSRAM)
ES (1) ES2708989T3 (OSRAM)
GB (1) GB2499480A (OSRAM)
HU (1) HUE042330T2 (OSRAM)
WO (1) WO2011121305A2 (OSRAM)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5869553B2 (ja) 2010-03-31 2016-02-24 スタビリテック リミテッド ウイルス粒子、ポリペプチド又は生体材料を安定化させる添加剤
JP5960120B2 (ja) 2010-03-31 2016-08-02 スタビリテック リミテッド ウイルス粒子の安定化
GB201117233D0 (en) 2011-10-05 2011-11-16 Stabilitech Ltd Stabilisation of polypeptides
GB201406569D0 (en) * 2014-04-11 2014-05-28 Stabilitech Ltd Vaccine compositions
US9588123B2 (en) * 2014-04-11 2017-03-07 Surmodics Ivd, Inc. Compositions and methods for in vitro diagnostic tests including zwitterionic solubilization reagent
GB2562241B (en) * 2017-05-08 2022-04-06 Stabilitech Biopharma Ltd Vaccine compositions
AR111760A1 (es) * 2017-05-19 2019-08-14 Novartis Ag Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral
CN113750228B (zh) * 2021-09-25 2024-02-20 大连理工大学 一种冷冻保护剂在铝佐剂中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1438874A (zh) * 2000-06-08 2003-08-27 宝德杰克特疫苗有限公司 粉末组合物
WO2005042029A2 (en) * 2003-10-27 2005-05-12 Psma Development Company, Llc Psma formulations and uses thereof

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3927208A (en) 1973-05-14 1975-12-16 Rit Rech Ind Therapeut Live bovine adenovirus vaccines, preparation thereof and method of vaccination using them
US4631189A (en) 1980-03-10 1986-12-23 Da Vinci Laboratories, a division of FoodScience Corporation N,N-dimethylglycine and use in immune response
JPS6013718A (ja) 1983-07-05 1985-01-24 Chemo Sero Therapeut Res Inst Ｂ型肝炎ワクチン
JPS60193925A (ja) 1984-03-13 1985-10-02 Chemo Sero Therapeut Res Inst 凍結乾燥製剤化ワクチン
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
JPS61189228A (ja) 1985-02-19 1986-08-22 Nippon Sekijiyuujishiya 血液凝固第８因子製剤の製法
US4950596A (en) 1985-03-04 1990-08-21 The Dow Chemical Company Stabilization of intracellular enzymes
JPS6238173A (ja) 1985-08-13 1987-02-19 三菱レイヨン株式会社 抗血液凝固剤
US5169758A (en) 1986-05-02 1992-12-08 Boehringer Mannheim Gmbh Stabilized, NAD(P)H-dependent, soluble nitrate reductase, a process for the preparation thereof and a reagent containing it
NZ221306A (en) 1986-08-15 1990-02-26 Commw Scient Ind Res Org 2-component immunoadjuvant comprising a mycobacterial free immunoadjuvant oil and a polycationic polyelectrolyte immunoadjuvant and vaccines thereof
ATE82506T1 (de) * 1987-08-21 1992-12-15 Imcera Group Inc Stabilisierung von wachstumshormonen.
GB8826429D0 (en) 1988-11-11 1988-12-14 Univ Leeds Ind Service Ltd Enzyme stabilisation systems
CA2065023A1 (en) 1989-08-15 1991-02-16 Brent Dorval Stabilized vaccine compositions
AU650045B2 (en) 1990-09-12 1994-06-09 Lifecell Corporation Method and apparatus for cryopreparation dry stabilization and rehydration of biological suspensions
ZA936095B (en) 1992-08-21 1994-03-14 Univ Melbourne Cytokine applications.
AU5543294A (en) 1993-10-29 1995-05-22 Pharmos Corp. Submicron emulsions as vaccine adjuvants
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
GB9521806D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
FR2746109B1 (fr) 1996-03-12 1998-04-17 Rhone Poulenc Rorer Sa Milieu pour la conservation de materiel biologique
CA2242035C (en) 1997-07-01 2004-11-23 Transgene S.A. Compositions useful for transferring therapeutically active substances into a target cell, and their use in gene therapy
KR20010032550A (ko) 1997-11-26 2001-04-25 유니버설 프리저베이션 테크놀로지스 인코포레이티드 유리화에 의한 민감한 생물학적 시료의 보존방법
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
ES2323991T3 (es) 1998-11-16 2009-07-28 Introgen Therapeutics, Inc. Formulacion de adenovirus para terapia genica.
AUPQ347199A0 (en) 1999-10-15 1999-11-11 Csl Limited Novel polypeptide fragments
DE10041515A1 (de) 2000-08-24 2002-03-14 Gerold Schuler Verfahren zur Herstellung gebrauchsfertiger, Antigen-beladener oder -unbeladener, kryokonservierter reifer dendritischer Zellen
US20040110267A1 (en) 2000-12-15 2004-06-10 Stratagene Room temperature stable competent cells
EP1399131A2 (en) 2001-06-08 2004-03-24 Powderject Vaccines, Inc. Spray freeze-dried compositions
US7101693B2 (en) 2001-09-07 2006-09-05 Brigham Young University Plasticized hydrophilic glasses for improved stabilization of biological agents
JP4936618B2 (ja) 2001-09-21 2012-05-23 株式会社ノエビア 微細エマルション組成物
EP1946776B1 (en) 2002-02-27 2017-01-18 Immunex Corporation Stabilized tnfr-fc composition comprising arginine
WO2004002534A1 (en) 2002-06-27 2004-01-08 Novo Nordisk A/S Use of dimethyl sulfone as isotonicity agent
CA2491805A1 (en) 2002-07-10 2004-01-22 Transgene S.A. Modified adenoviral fiber with ablated binding to cellular receptors
AU2003272174A1 (en) 2002-10-21 2004-05-04 Biotage Ab Use of osmolytes to heat stabilise luciferase and/or apyrase
JP2006521084A (ja) 2002-12-10 2006-09-21 シェーリング−プラウ・リミテッド イヌｒａｎｋｌならびにイヌｒａｎｋｌを調製および使用するための方法
US20060247167A1 (en) 2003-09-01 2006-11-02 Novo Nordisk A/S Stable formulations of peptides
US7642077B2 (en) 2003-12-08 2010-01-05 Genencor International, Inc. Biocomposite comprising co-precipitate of enzyme, silicate and polyamine
WO2005062709A2 (en) 2003-12-30 2005-07-14 Virumar Pituach Tarkivim Ltd. Integrated viral complexes, methods of production thereof, vaccines containing same and methods of use thereof
SG150570A1 (en) 2004-03-03 2009-03-30 Revance Therapeutics Inc Compositions and methods for topical diagnostic and therapeutic transport
US20060058238A1 (en) 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
EP3173072A1 (en) 2004-10-01 2017-05-31 Ramscor, Inc. Conveniently implantable sustained release drug compositions
KR20070107079A (ko) 2005-01-28 2007-11-06 와이어쓰 안정화된 액체 폴리펩타이드 제형
GB0502661D0 (en) 2005-02-09 2005-03-16 Stabilitech Ltd A desiccated product
TWI398272B (zh) 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
KR20150032915A (ko) 2005-04-08 2015-03-30 아르고스 쎄라퓨틱스 인코포레이티드 수지상 세포 조성물 및 방법
EP1933867A1 (en) 2005-10-04 2008-06-25 Alk-Abello A/S Solid vaccine formulation
JP5138601B2 (ja) 2005-11-21 2013-02-06 サノフィ パストゥール リミテッド 組換えウイルス安定化製剤
ES2352855T3 (es) 2005-11-30 2011-02-23 International Institute Of Cancer Immunology, Inc. Nuevos compuestos peptídicos del tumor de wilms.
WO2008051245A2 (en) 2005-12-02 2008-05-02 Novartis Ag Nanoparticles for use in immunogenic compositions
EP1987067A4 (en) * 2006-02-15 2012-01-25 Imclone Llc ANTIBODY FORMULATION
ES2286951B1 (es) * 2006-05-26 2008-10-01 Instituto Cientifico Y Tecnologico De Navarra, S.A Nanoparticulas bioadhesivas para la administracion de moleculas biologicamente activas.
CA2668417A1 (en) 2006-11-03 2008-05-15 Alphavax, Inc. Alphavirus and alphavirus replicon particle formulations and methods
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
EP2829282B1 (en) * 2007-03-22 2017-10-25 The Regents of The University of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
EP2150537A4 (en) * 2007-06-01 2010-09-22 Acologix Inc STABLE PEPTIDE FORMULATION AT HIGH TEMPERATURE
EP2192908A4 (en) * 2007-07-25 2010-09-01 Bioe Inc DIFFERENTIATION OF PRECURSOR CELLS OF MULTIPLE ABSTRACTS AGAINST CHONDROCYTES
US20090123436A1 (en) 2007-11-08 2009-05-14 Surmodics, Inc. Cryopreservative compositions and methods
JP2012503637A (ja) 2008-09-24 2012-02-09 スタビリテック リミテッド 糖およびポリエチレンイミンを使用するポリペプチドの保存方法
US20110212127A1 (en) 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
CN101670104A (zh) 2009-09-24 2010-03-17 浙江大学 一种含人参皂甙的油佐剂及其制备方法
JP5960120B2 (ja) 2010-03-31 2016-08-02 スタビリテック リミテッド ウイルス粒子の安定化

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1438874A (zh) * 2000-06-08 2003-08-27 宝德杰克特疫苗有限公司 粉末组合物
WO2005042029A2 (en) * 2003-10-27 2005-05-12 Psma Development Company, Llc Psma formulations and uses thereof

Also Published As

Publication number Publication date
WO2011121305A2 (en) 2011-10-06
KR20130012956A (ko) 2013-02-05
AU2011234268A1 (en) 2012-09-27
WO2011121305A3 (en) 2011-11-24
JP2013523705A (ja) 2013-06-17
HUE042330T2 (hu) 2019-06-28
JP6023696B2 (ja) 2016-11-09
US20130156797A1 (en) 2013-06-20
AU2011234268B2 (en) 2015-07-02
GB2499480A (en) 2013-08-21
CA2795050A1 (en) 2011-10-06
CN102892409A (zh) 2013-01-23
KR101819250B1 (ko) 2018-01-16
BR112012025044A2 (pt) 2016-06-21
ES2708989T3 (es) 2019-04-12
US9101607B2 (en) 2015-08-11
DK2552410T3 (en) 2019-02-18
GB201216472D0 (en) 2012-10-31
EP2552410B1 (en) 2018-10-24
EP2552410A2 (en) 2013-02-06
CA2795050C (en) 2018-05-22

Similar Documents

Publication Publication Date Title
CN102892409A (zh) 用于保存铝盐佐剂和铝盐-佐剂化疫苗的方法
JP4902103B2 (ja) 凍結乾燥フォームによる生物活性材料の保存
US8795686B2 (en) Stable, dried rotavirus vaccine, compositions and process for preparation thereof
JP4142095B2 (ja) 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物
Clausi et al. Inhibition of aggregation of aluminum hydroxide adjuvant during freezing and drying
CN101146518B (zh) 化学限定的稳定剂组合物的制备方法
CA2680193C (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof
CN106063933B (zh) 通用疫苗冻干保护剂及其应用
KR20110007099A (ko) 항원보강제 함유 백신 조성물의 안정화 방법
IL189402A (en) Method of producing a dry powder comprising a cellular material and powder produced by such method
JP2024532292A (ja) 脂質ナノエマルション粒子に吸着したｍＲＮＡの凍結乾燥製剤
AU2005225000A1 (en) Lyophilization method to improve excipient crystallization
EP2461679B1 (en) Vaccine stabilizer
EA050946B1 (ru) ЛИОФИЛИЗИРОВАННЫЕ ПРЕПАРАТЫ мРНК, АДСОРБИРОВАННОЙ НА ЛИПИДНЫХ ЧАСТИЦАХ НАНОЭМУЛЬСИИ
Clausi Lyophilized vaccine preparations containing aluminum salt adjuvants: Preparation, immunogenicity, and stability
Cottle Development of methods and formulation for maintaining aluminum salt adjuvant stability and adsorption capacity during freeze-drying
HK1139076B (en) Lyophilized preparation comprising influenza vaccine, and method for preparation thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20151209

CF01 Termination of patent right due to non-payment of annual fee